A prescription drug bill that cleared the U.S. House last week seeks to curb skyrocketing drug prices charged by large pharmaceutical firms. But the price controls could work against Connecticut’s push to grow its bioscience sector by driving investors away from the small startups that comprise much of the industry here, local biotech leaders say.